The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - holding patents (8999996, 9079865, 9714226, PCT/US12/048319, and I574957) on hydrazide-containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 2012000928) on hydrazide-containing nuclear tr
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
 
Yazmin Odia
Consulting or Advisory Role - Abbvie; GammaTile
Research Funding - Bristol-Myers Squibb (Inst); Novocure (Inst)
Travel, Accommodations, Expenses - Novocure
 
Samuel Aaron Goldlust
Stock and Other Ownership Interests - COTA
Honoraria - Bristol-Myers Squibb; Novocure; Tocagen; Wex Pharmaceuticals
Consulting or Advisory Role - Boston Biomedical; Bristol-Myers Squibb; Cortice Biosciences; Novocure; Tocagen; Wex Pharmaceuticals
Speakers' Bureau - Novocure
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cantex Pharmaceuticals (Inst); Celgene (Inst); Celldex (Inst); CNS Healthcare (Inst); Cortice Biosciences (Inst); Diffusion Pharmaceuticals (Inst); ImmunoCellular Therapeutics (Inst); Imvax (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Novogen (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Tocagen (Inst); Wex Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Boston Biomedical; Bristol-Myers Squibb; Caris Life Sciences; Cortice Biosciences; Kyowa Kirin International; Novocure; Tocagen; Wex Pharmaceuticals
 
Minesh P. Mehta
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Consulting or Advisory Role - Karyopharm Therapeutics; Mevion Medical Systems; Sapience Therapeutics; Tocagen; ZappRx
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
(OPTIONAL) Uncompensated Relationships - ViewRay; Xcision Medical Systems
 
Andrew B. Lassman
Honoraria - Abbott Molecular
Consulting or Advisory Role - Bayer; BioClinica; Elsevier; FORMA Therapeutics; Karyopharm Therapeutics; Novocure; Orbus Therapeutics; QED Therapeutics; Sapience Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Bayer (Inst); BeiGene (Inst); BMS (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); RTOG Foundation (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Abbott Molecular; AbbVie; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Novartis; Orbus Therapeutics; Pfizer; QED Therapeutics
 
Howard Colman
Consulting or Advisory Role - Abbvie; Adastra Pharmaceuticals; Bayer; Best Doctors, Inc; FORMA Therapeutics; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bayer; BeiGene (Inst); Bristol-Myers Squibb; DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Nuvation Bio; Orbus Therapeutics (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; FORMA Therapeutics; Karyopharm Therapeutics; Orbus Therapeutics
 
Priya Kumthekar
Stock and Other Ownership Interests - Vivacitas Oncology
Consulting or Advisory Role - Biocept; Biocept; ElevateBio; Janssen; Novocure; Orbus Therapeutics
Research Funding - Angiochem; DNAtrix; Genentech; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Warren P. Mason
Consulting or Advisory Role - GlaxoSmithKline
 
Rebecca A. Harrison
No Relationships to Disclose
 
Nicholas A. Butowski
Stock and Other Ownership Interests - Cordance; Cordance
Consulting or Advisory Role - Amgen; Cellinta; DelMar Pharmaceuticals; Karyopharm Therapeutics; KIYATEC; Lynx Group; Plus Therapeutics; QED Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Research Funding - Abbvie (Inst); Amgen; Amgen (Inst); Arbor Pharmaceuticals (Inst); BeiGene (Inst); BeiGene (Inst); BioMimetix (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EpicentRx; Five Prime Therapeutics; Ipsen; Istari (Inst); KIYATEC (Inst); Medicenna; Merck; Oncoceutics (Inst); Orbus Therapeutics; Tocagen (Inst)
 
Vyshak Venur
Honoraria - Elsevier
Consulting or Advisory Role - Seagen
 
Scott Randall Plotkin
Stock and Other Ownership Interests - NF2 Therapeutics; NFlection Therapeutics; SonaCare Medical
Consulting or Advisory Role - Akouos; AstraZeneca; NFlection Therapeutics; SonaCare Medical
Research Funding - AstraZeneca; Pfizer; Takeda (Inst)
Travel, Accommodations, Expenses - NFlection Therapeutics
(OPTIONAL) Uncompensated Relationships - Pfizer (Inst)
 
Michael Schulder
No Relationships to Disclose
 
John A Boockvar
No Relationships to Disclose
 
J Paul Duic
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Kai Li
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Yang Liu
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Tamir
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Gregory Mundy
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)